Senior Scientist ASG

OXB; Oxford; On-site; GBP 40,000 - 60,000; Full time

Job summary

A leading company in viral vector manufacturing is seeking a Senior Scientist I / II to support analytical method transfer within Quality Control. The ideal candidate will facilitate client work packages while mentoring the team and ensuring high standards in assay management. This desk-based role focuses on innovative approaches in a collaborative atmosphere.

Benefits

Highly competitive total reward packages

Wellbeing programmes

Development opportunities

Diverse and inclusive working environment

State of the art laboratory facilities

Qualifications

• Experience in multiple analytical techniques like ELISA, qPCR, cell-based assays.
• Management and delivery of technical projects in regulated environments.
• Strong writing skills for report preparation.

Responsibilities

• Transfer new assays from ADG to QC ensuring scientific soundness.
• Manage analytical spreadsheets for result calculation.
• Investigate assay-related problems and trends.

Skills

Analytical techniques

Critical thinking

Trouble-shooting

Communication

Microsoft Excel

Education

BSc, MSc, or PhD in Biosciences or related field

Job description

Job description:

We use science to save lives, and so can you.

We are currently recruiting for a Senior Scientist I / II to join the Analytical Sciences and Technology (AST) team within the Quality Control (QC) department. The purpose of this role is to lead and support the transfer of analytical methods used in the testing of lentiviral vectors for cell and gene therapy products from development to QC. You'll help deliver client work packages and mentor other scientists while contributing to continuous innovation in assay lifecycle management.

Our AST team supports the development of products through analytical testing to facilitate manufacturing, ensuring appropriate quality controls and use of analytics.

Please note, this is an desk-based role.

Your responsibilities in this role would be:

• Transfer of new assays from ADG (Analytical Development Group) to QC, ensuring that the assays are scientifically sound and fit-for-use in GMP.
• Management of analytical spreadsheets required for calculation of results.
• Management and justification of assay acceptance criteria.
• Management of in-house control materials, including qualification studies to ensure fit-for-use.
• Monitoring of assay performance and investigation of any observed trends.
• Responsible for thorough and timely investigation of invalid assays.
• Responsible for thorough and timely investigation of OOS, OOE and OOT events.
• Responsible for trouble-shooting any assay-related problem inhibiting the reporting of results.

We are looking for:

• A BSc, MSc, or PhD in a Biosciences or related field, with experience in multiple analytical techniques (ELISA, qPCR, cell-based assays).
• Demonstrated ability to manage and deliver technical projects in a regulated or GxP environment.
• Proven abilities in critical thinking and trouble-shooting.
• Strong working knowledge of Microsoft Excel.
• Excellent writing skills for preparing plans and reports.
• Experience of working within a GMP environment an advantage.
• Strong communication skills and experience liaising with cross-functional teams and clients.
• A collaborative, proactive mindset and a commitment to high scientific standards.

About Us:

OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors—the driving force behind the majority of gene therapies.

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Our world-class capabilities span from early-stage development to commercialisation, supported by robust quality-assurance systems, analytical methods, and regulatory expertise.

About Us:

OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

What’s in it for you:

• Highly competitive total reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Responsible, Responsive, Resilient, Respect
• State of the art laboratory and manufacturing facilities

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.

Collaborate. Contribute. Change lives

#LI-SCM1

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.